title: Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.
abstract: BACKGROUND
  Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Spain.
  
  
  METHODS
  A cost analysis model was developed to compare glatiramer acetate and fingolimod, based on a 1-year time horizon. In addition to the pharmacological costs, resource use was estimated for glatiramer acetate (1 hour of training with nursing staff in self-injection techniques for subcutaneous administration) and fingolimod (vaccination for varicella-zoster virus in 5% of patients, 3 complete blood counts per year, 3 ophthalmology visits for prevention of macular edema, 3 transaminase tests to monitor liver function, and cardiovascular monitoring consisting of 1 ECG before the first fingolimod dose and at 6 hours; 1 day outpatients-hospital visit for cardiological monitoring during 6 hours on the day of the first fingolimod dose, with follow-up of blood pressure and heart rate every hour). The pharmacological costs were calculated based on the ex-factory price of the drugs evaluated, using the doses recommended in the respective Summary of Products Characteristics (SmPC). Total invoicing volume was discounted by 7.5%, as laid down in Spanish Royal Decree 8/2010. Unit costs were obtained from the e-Salud database and the drug catalog. Costs in the model are expressed in €2012.
  
  
  RESULTS
  The cost of annual treatment was €9,439.42 for glatiramer acetate and €19,602.18 for fingolimod, yielding a cost difference of €10,162.76. Assuming a fixed budget of €100,000.00, approximately 10 patients could be treated with glatiramer acetate, compared to 5 with fingolimod.
  
  
  CONCLUSIONS
  Fingolimod therapy requires twice the investment as glatiramer acetate.
authors: Medical & HEOR Department, TEVA Pharmaceutical, Calle Anabel Segura, 11-1ª planta, Alcobendas, Madrid, 28108, Spain.
authors: Rainel
authors: R
authors: Sanchez-de la Rosa
authors: Pharmacoeconomics and Outcomes Research Iberia Edificio CEP Altagracia I Calle Segundo Mata, 1 (2ª Planta), Pozuelo de Alarcón, Madrid, 28224, Spain.
authors: Eliazar
authors: E
authors: Sabater
authors: Pharmacoeconomics and Outcomes Research Iberia Edificio CEP Altagracia I Calle Segundo Mata, 1 (2ª Planta), Pozuelo de Alarcón, Madrid, 28224, Spain.
authors: Miguel A
authors: MA
authors: Casado
keywords: Cost analysis model; Economic evaluation; Fingolimod; Glatiramer acetate; Relapsing-remitting multiple sclerosis (RRMS)
references: Mult Scler. 2012 Mar;18(3):372-6
references: 21878452
references: Rev Neurol. 2011 Aug 1;53(3):129-38
references: 21748710
references: Adv Ther. 2009 May;26(5):552-62
references: 19444392
references: Neurologia. 2010 Jul-Aug;25(6):378-90
references: 20738958
references: J Neurol. 2008 Sep;255(9):1354-60
references: 18677639
references: Eur J Health Econ. 2006 Sep;7 Suppl 2:S65-74
references: 17310340
references: Pharmacoeconomics. 2001;19(6):609-21
references: 11456210
references: J Cent Nerv Syst Dis. 2012 Aug 29;4:117-33
references: 23650472
references: Mult Scler. 2013 Feb;19(2):245-8
references: 22546846
references: N Engl J Med. 2000 Sep 28;343(13):938-52
references: 11006371
references: J Manag Care Pharm. 2007 Jan-Feb;13(1):44-52
references: 17269836